Print

KaloBios Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies  
3/23/2011 10:19:54 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneeredâ„¢ monoclonal antibody, in EphA3-expressing hematologic malignancies.
//-->